Paratek enters commercial stage with 2 FDA antibiotics nods by Angus Liu Wednesday, October 3, 2018 Nuzyra, approved for CABP and ABSSSI, represents the first in a new chemical class within tetracycline, with peak sales projected at over $500 million.
